Login to Your Account

Neurocrine Facing Setback, Too

VaxGen Shares Nosedive On Anthrax Vaccine Stall

By Randall Osborne

Monday, November 6, 2006
The latest snag for VaxGen's anthrax vaccine sent shares down by more than half after the company said the FDA put rPA102 on clinical hold, delaying the second Phase II trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription